Data on post-transplant iron overload (IO) are scarce in pediatrics. We conducted a prospective multicenter cohort study (Leucémie de l'Enfant et de l'Adolescent cohort) to determine the prevalence and risk factors of IO in 384 acute leukemia survivors transplanted during childhood. Prevalence of IO (ferritin level ⩾ 350 ng/mL) was 42.2% (95%CI 37.2-47.2%). Factors significantly associated with IO were: 1) in univariate analysis: older age at transplant (Po 0.001), allogeneic versus autologous transplantation (P o0.001), radiation-based preparative regimen (P = 0.035) and recent period of transplantation (P o 0.001); 2) in multivariate analysis: older age at transplant in quartiles (Odds Ratio (OR) = 7.64, 95% CI: 3.73-15.64 for age 412.7 years and OR = 5.36, 95% CI: 2.63-10.95 for age from 8.2 to 12.7 years compared to age o 4.7 years), acute myeloid leukemia (OR = 3.23, 95% CI: 1.47-7.13), allogeneic graft (OR = 4.34, 95% CI: 2.07-9.12 for alternative donors and OR = 2.53, 95% CI: 1.2-5.33 for siblings, compared to autologous graft) and radiation-based conditioning regimen (OR = 2.45, 95% CI: 1.09-5.53). Graft-versus-host disease was an additional risk factor for allogeneic graft recipients. In conclusion, IO is a frequent complication in pediatric long-term survivors after transplantation for acute leukemia, more frequently observed in older children, those transplanted from alternative donors or with graft-versus-host disease.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a curative therapy for children with high-risk acute leukemia (AL). Owing to significant advances in transplant techniques and supportive care over the last two decades, a large number of children become long-term survivors, at risk of late effects. 1, 2 These complications impair their quality of life and generate morbidity and mortality, often a long time after transplantation. Iron overload (IO), whose incidence is estimated between 30 and 60% in adults transplanted for hematological malignancies, [3] [4] [5] is recognized as a complication of HSCT. If iterative red blood cell transfusions remain the main cause of IO, other mechanisms specific to HSCT, such as ineffective erythropoiesis or dysregulation of hepcidin, have been described. [6] [7] [8] [9] [10] IO may impact the outcome of allogeneic HSCT. [11] [12] [13] [14] Even if an elevated serum ferritin level (SFL) is considered to be a risk factor for hepatic sinusoidal obstruction syndrome, abnormal liver function, 15, 16 mucositis, 17 infections, [18] [19] [20] [21] or an increased mortality, 22 it remains difficult to incriminate IO as the only factor, due to the overlapping toxicity profiles among chemo/ radiotherapy, GvHD and IO. 1, 2 Published data on IO in children transplanted for hematological malignancies are scarce. 23, 24 Chotsampancharoen et al. 25 reported the results of a pediatric prospective study in which 93.2% of 133 survivors after HSCT for leukemia had a SFL superior to the upper limit of the normal range and 40% had a SFL 41000 μg/L. High SFLs were positively correlated with liver, cardiac or endocrine abnormalities. Our study aimed to determine the prevalence and risk factors of IO in a multicenter prospective cohort of 384 AL survivors transplanted during childhood.
PATIENTS AND METHODS

Inclusion criteria
The 'Leucémie de l'Enfant et de l'Adolescent' cohort (L.E.A.) aims to evaluate the long-term health status, quality of life, psychological and socioeconomic status by a clinical examination and a questionnaire to be completed by the parents and/or the patient in all childhood acute leukemia (AL) survivors treated since 1980. 26 This program based on the constitution of a French multicenter historical and prospective cohort, began in 2004 and includes both incident cases (diagnosed after the start date of the participation of the center in the LEA program) and prevalent cases (diagnosed between 01/01/1980 and this start date). For incident cases, the information is collected in a prospective way according to a fixed schedule. For prevalent cases, it is collected prospectively only after their inclusion. Visits begin at least one year after the end of treatment, and are repeated every 2 years until the age of 20 and at least 10 years of complete remission (CR), and every 4 years thereafter. Since 2007, measure of SFL with erythrocyte sedimentation rate (ESR) was performed to evaluate IO. All patients or their parents provided written informed consent. This study was approved by the French National Program for clinical research and the French National Cancer Institute.
Patients evaluated in the LEA program between 2007 and 2012 were eligible for this study if: (I) they had undergone allogeneic or autologous HSCT (II) they had received a myeloablative conditioning regimen (III) they were in CR at the time of LEA evaluation. For a more accurate evaluation of IO, 9 patients who relapsed after transplant and 22 patients who had undergone more than one transplant were excluded. Four deceased patients were included until their death. Transplantations were performed from April 23th, 1982 to the December 21th, 2011.
Assessment of iron overload
IO diagnosis was defined as at least one value of SFL ⩾ 350 ng/mL with an ESR at one hour o50 mm. This value is slightly above the upper limit of the normal range of most laboratories. A SFL ⩾ 1000 ng/mL was also considered for statistical analysis since it represents the usually accepted threshold for starting chelation.
In the case of hyperferritinemia, the first value and date of detection of SFL ⩾ 350 ng/mL, initiation, nature, and duration of a therapy for IO were recorded. Evaluation of liver iron concentration (LIC) by resonance magnetic imaging (MRI) was recommended in patients with IO.
Statistical analysis
Primary endpoint was IO prevalence defined with each of the aforementioned SFL thresholds. Endpoints were analyzed in the whole cohort and in the subgroup of allogeneic transplants. Prevalence rates were displayed with their 95% confidence intervals (CI). Patient characteristics were described as mean ± standard error for quantitative variables and numbers and frequencies for qualitative variables. They were compared between included and non-included patients to assess potential selection bias, then between patients with and without IO. χ 2 and Fischer's exact tests were used to compare qualitative variables and Student or Mann-Whitney tests for quantitative variables. Variables tested in univariate analyses for their potential correlation with IO were gender, age at transplant in quartiles, AL type, type of transplant, conditioning regimen with/without radiation, disease status at transplant, period of transplant in quartiles and for the allogeneic subgroup, significant GvHD defined as a previous or current diagnosis of grade II to IV acute GvHD and/or extensive chronic GvHD. Multivariate logistic regression models for IO included the type of leukemia as well as variables significant in at least one univariate analysis (P-value ⩽ 0.05). Odds ratios (OR) were estimated with their 95% CI and the significance threshold was set as Po0.05. Statistical analyses were performed during February, 2014, using SPSS 20.0 (SPSS Inc., Chicago, IL, USA) and Intercooled Stata 9.0 for Windows.
RESULTS
Studied cohort
Of the 420 LEA patients who fulfilled the inclusion criteria, 384 (91.43%) had at least one ferritin value and were included in this study. Among them, 127 had at least 2 ferritin evaluations (range: 1-4, IQR 1-2). Comparison of the characteristics between included (n = 384) and non-included patients (n = 36) showed no statistical difference except for time from transplantation to last visit (P = 0.007) ( Table 1) .
Patient characteristics are detailed in Table 1 . Mean age at transplant was 8.8 ± 0.3 years and mean follow-up duration was 10 ± 0.4 years. 205 (53.4%) patients were transplanted in first CR. 257 (69.9%) patients received a radiation-based conditioning regimen. 322 (83.9%) patients were transplanted from matched sibling donors or alternative donors, which encompassed mismatched familial or unrelated donors or cord blood grafts. Significant GvHD was observed in 140 allogeneic graft recipients (43.5%). Abbreviations: ALL = acute lymphoblastic leukemia; AML = acute myeloblastic leukemia; Bu = busulfan; CR = complete remission; GvHD = graft-versus-host disease; s.e. = standard error; TBI = total body irradiation. a HLA-mismatch familial donors, unrelated donors or cord blood grafts. b grade II-IV acute GVHD and/or extensive chronic GVHD. Bold values indicate statistically significant P-value.
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Overall prevalence and risk factors of iron overload in the LEA cohort Overall, 162 (42.2%, 95%CI 37.2-47.2%) patients had a SFL ⩾ 350 ng/mL and 51 (13.3%, 95% CI 10.1-17.2%) patients had a SFL ⩾ 1000 ng/mL. At time of diagnosis (first SFL ⩾ 350 ng/mL), the mean SFL reached 1038 ± 126 ng/mL. Univariate analysis revealed that variables significantly associated with a SFL ⩾ 350 ng/mL were an older age at transplant (Po0.001), an allogeneic transplantation (Po0.001), a radiation-based preparative regimen (P = 0.035) and a more recent period of transplantation (classified according to quartiles, Po0.001) ( Table 2 ). The variables significantly associated with a SFL ⩾ 1000 ng/mL in univariate analysis were an older age at transplant (Po0.001), status at transplant beyond the first CR (P = 0.029) and a more recent period of transplantation (Po0.001) ( Table 2) .
For the multivariate analysis, age at transplant, type of leukemia, pre-transplant disease status, type of transplant and preparative regimen were considered for both SFL. As the period of transplant was strongly linked to the type of graft, only the type of transplant was entered. Indeed, distribution between autologous and allogeneic transplantations has varied over time (Table 3) . Risk factors which significantly correlated with a SFL ⩾ 350ng/mL were an older age at transplant, a diagnosis of AML, an allogeneic graft and a radiation-based conditioning regimen (Table 4) . Risk factors of SFL ⩾ 1000 ng/mL were: an older age at transplant and a history of relapse before transplant (Table 4) .
Risk factors in the allogeneic group Considering only the subgroup of allogeneic graft recipients, older age at transplant (Po 0.001), period of transplant (P o0.001), Iron overload after HSCT during childhood for AL A Sirvent et al alternative donors (P = 0.045) and significant GvHD (P = 0.034) were significantly correlated with a higher prevalence of IO in univariate analysis (Table 5 ). Considering SFL ⩾ 1000 ng/mL, only an older age at transplant (P o 0.001) and period of transplant (P = 0.002) remained risk factors. The multivariate model included the aforementioned variables as well as the presence of a significant GvHD. An older age at transplant, grafts from alternative donors and presence of significant GvHD remained significant risk factors for a SFL ⩾ 350 ng/mL (Table 6 ). Only an age at transplant 412.7 years was significantly associated with a SFL ⩾ 1000 ng/mL (Table 6 ).
Evaluation of liver iron concentration Among the 162 patients with a SFL ⩾ 350 ng/mL, 17 underwent an evaluation of LIC by hepatic MRI. LIC was above the upper limit of the normal range (ie 2 mg/gdw) in 17/17 patients. The mean of LIC was 11.31 ± 1.51 mg/gdw. Nevertheless, we did find a statistically significant correlation between SFL and LIC.
Iron overload according to time of evaluation in the posttransplant period As shown in Figure 1a , the percentage of patients with a SFL ⩾ 350 ng/mL gradually decreased with the elapsed time from transplant (P o 0.001). Similarly, there was a statistically significant negative correlation between SFL and the time of its dosage in the post-transplant period (P o0.001, Figure 1b) . 68 iron-overloaded patients without any treatment for IO had at least 2 ferritin measures. The SFL spontaneously decreased from a mean value of 883ng/mL at the first evaluation to a mean value of 581 ng/mL at the last evaluation (Po 0.001, Figure 1c) . The mean time between the 2 evaluations was 3.68 years.
Treatments of IO in the LEA cohort Of the 162 patients with a SFL ⩾ 350 μg/L, 17 received a treatment. Eleven patients underwent phlebotomy, 4 received deferasirox and one deferiprone. One was treated with phlebotomy and deferasirox. Mean SFL was 1192 ng/mL at initiation of treatment and dropped to 681 at time of last ferritin dosage, mean follow-up between initiation of treatment and last ferritin dosage being 3.8 years. For patients treated with phlebotomy, the mean SFL at the initiation of treatment was 1013 ng/mL, 601 at the last evaluation, with a mean follow-up of 4.05 years. For the patients who received deferasirox, the mean SFL was 1571 ng/mL at the start of treatment, 704 at the last evaluation, with a mean follow-up of 2.27 years.
DISCUSSION
Our study was designed to analyze the prevalence and risk factors of IO beyond one year post transplant in a large prospective and homogeneous cohort of long-term childhood AL survivors. Patients with an AL require red blood cell transfusions during their treatment, and may become iron overloaded. A review of the transfusion records in a cohort of 881 long-term survivors of childhood hematological malignancies treated at the St Jude hospital showed that a substantial transfusion volume was delivered, significantly higher in patients with AML compared to ALL, and in HSCT survivors. 27 Therefore, several cooperative groups recommend monitoring of IO after HSCT by measuring ferritin annually [28] [29] [30] although ferritin is an imperfect surrogate measure of total body iron. 31 Indeed, many confounding factors, 32 such as inflammatory processes, GVHD, drug toxicity, often observed in the early post-transplant period, can increase ferritin levels. To circumvent this bias, all patients included in our study were beyond the first year post transplant and had an ESR at one hour o 50 mm. Quantification of hepatic iron, using hepatic MRI, provides a more accurate measure of body iron burden. 33 We performed hepatic MRI in only 17 of the 162 patients with a SFL ⩾ 350 ng/mL and found an increased LIC in all of them. The low number of MRI performed in our study may probably explain the lack of correlation between LIC and the ferritin value. A positive Abbreviations: ALL = acute lymphoblastic leukemia; AML = acute myeloblastic leukemia; Bu = busulfan; CI = confidence interval; CR = complete remission; OR = odd ratio; SFL = serum ferritin level; TBI = total body irradiation. Iron overload after HSCT during childhood for AL A Sirvent et al correlation has been reported by Rose et al. 5 in 65 long-term survivors after allogeneic HSCT.
We report a SFL exceeding 350 in 42.2% and 1000 ng/mL in 13.3% of 384 HSCT long-term survivors, with a mean follow-up of 10.0 ± 0.35 years from HSCT to last visit. Our results are in agreement with those previously published, although large prospective studies aiming to assess IO after HSCT are still limited and mainly concern adult patients. Majhail et al. 3 found a SFL ⩾ 1000 ng/mL in 34% of 56 patients after a median follow-up of 28 months since transplantation. Similarly, Rose et al. 5 reported a ferritin value above normal range in 58% of 65 patients after a median follow-up of 8.8 years. Focusing on pediatric population, ferritin value was found beyond normal range in 93.2% of 133 survivors of childhood leukemia one year after allogeneic transplantation, followed by a slow decline over time thereafter. 25 Pre-and post-transplant SFL are directly related to the volume of RBC transfusions. 5, 24 Although we have no data on the volume of transfusions, we can speculate that children enrolled in our study were transplanted for high-risk leukemia and thus largely transfused. Beside this main cause of IO, other mechanisms may contribute to the disruption of normal iron homeostasis and amplify the risk of secondary hemochromatosis after HSCT: increased intestinal iron absorption, related to an aberrant hepcidin regulation [8] [9] [10] but also to chemotherapy and GvHD-induced intestinal epithelial injury, underutilization of iron pools as a result of ineffective erythropoiesis, release of iron from bone marrow and liver cells due to chemo/radiotherapy 6, 7 and finally decreased hepcidin's hepatic secretion consecutive to immunosuppressive therapy, acute hepatic GvHD. 9, 34 An older age at HSCT led to a significantly higher risk of IO in univariate and multivariate analyses, whatever the ferritin threshold considered. This risk factor was not found in other studies. Several assumptions may explain this finding. In ALL, age above 10 years is a poor prognostic factor that may justify escalating chemotherapy in many therapeutic protocols. These intensified protocols applied to older children result in a greater hematological toxicity, hence more transfusions. 35 Secondly, the extra-hematological toxicity of the conditioning regimen, including intestinal and hepatic injury, more severe in older children, may contribute to the higher incidence of IO. 6 Finally, iron uptake for growth which facilitates reduction in iron stores over time in young children, seems less powerful in older children.
Allogeneic transplantation compared to autologous transplantation was a major risk factor for IO. 6, 36 Several reasons can explain this feature. The absence of GvHD and immunosuppressive therapy, which have been shown to induce IO, may be a first hypothesis. Most autologous transplants performed before 2002, used marrow stem cell. During the early post-transplant period, children probably received an equivalent volume of transfusions to that given after allogeneic trans- 
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Gender, n (%) Abbreviations: ALL = acute lymphoblastic leukemia; AML = acute myeloblastic leukemia; Bu = busulfan; CR = complete remission; GVHD = graft-versus-host disease; SFL = serum ferritin level; TBI = total body irradiation. Iron overload after HSCT during childhood for AL A Sirvent et al plantation. However, due to the lack of immunological complications and a lower incidence of infectious complications, the need for transfusions rapidly decreases after hematological recovery, resulting in a total blood supply inferior to that after allogeneic transplantation. Finally, as autologous transplant recipients included in this cohort had a long follow-up, we can hypothesize that IO has resolved spontaneously. Children transplanted from an alternative donor had a significantly higher risk of IO than those transplanted from an HLA-identical sibling. Chotsampancharoen et al. 25 also found higher SFL after a matched unrelated transplantation. HLA disparity between donor and recipient has been associated with an increased incidence of GvHD and infections, slower engraftment, all favoring IO. 37, 38 A more recent period of transplantation was significantly correlated with a higher risk of IO in our cohort. This result cannot be explained by a change in transfusion guidelines. However, it may result from a modification of transplant techniques: as shown in our study, autologous transplantations were progressively supplanted by allogeneic transplantations initially from sibling donors and then from alternative donors. We demonstrated that allogeneic HSCT long-term survivors from alternative donors were at higher risk of IO. Another explanation is the use, during the past decade, of more intensive therapeutic protocols for AL, which induce more profound myelosuppression, hence tremendous blood product support, more severe ineffective erythropoiesis with an underutilization of the pool of iron and an excess release of iron by bone marrow and liver cells due to toxic effects. Ruccione et al. 35 found that higher treatment intensity scores were associated with more transfusions in 214 children treated for hematological and solid malignancies. Nottage et al. 27 showed that recent survivors (5-10 years) were twice as likely to have received 10 or more transfusions than survivors of more than 10 years follow-up. They concluded that the number of transfusions increased with increasing Intensity of Treatment Rating Scale version 3 score and with a more recent decade of treatment. Finally, we can speculate that serum ferritin slowly declines over time: we found that the proportion of children with a SFL ⩾ 350 ng/mL gradually decreased according to time of evaluation as well as a negative correlation between SFL and time of evaluation. In parallel, the SFL significantly decreased over time in the group of non-treated iron overloaded patients who had at least 2 ferritin measures. The spontaneous improvement of iron parameters has already been reported in adults by Meyer et al. 22 and in children by Chotsampancharoen et al. 25 . Increased endogenous mobilization and utilization of stored and transportable iron along with reduced intestinal iron absorption may be potential mechanisms leading to ferritin decline.
We have demonstrated that a history of significant GvHD was a risk factor for IO. GvHD may lead to an elevated SFL by marrow hypoplasia, chronic inflammatory stimuli, intestinal and/or hepatic injury and the use of immunosuppressive drugs which are known to modify hepcidin's regulation. 10 Likewise, patients prepared with TBI had a significantly higher prevalence of IO compared to chemotherapy-based regimens. This risk factor has not yet been reported. Intestinal and/or hepatic toxicity generated by radiation may be a potential explanation.
We have very few data concerning the therapeutic management of our patients. As previously reported, phlebotomy and deferasirox were the most frequently used treatments, successful in significantly reducing SFL. [39] [40] [41] [42] In conclusion, we observed a high prevalence of IO in long-term survivors transplanted for an AL during childhood. This long lasting late effect (up to 10 years after transplant) emphasizes the need for screening this complication in transplanted children. As there is a substantial overlap between the conditioning-induced Abbreviations: ALL = acute lymphoblastic leukemia; AML = acute myeloblastic leukemia; Bu = busulfan; CI = confidence interval; CR = complete remission; GVHD = graft-versus-host disease; OR = Odd ratio; SFL = serum ferritin level; TBI = total body irradiation. 
